Immunotherapy of cancer: A perspective view
โ Scribed by R. A. Reisfeld
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 692 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
โฆ Synopsis
The current intense interest in cancer immunotherapy is largely based on the fact that progress in the clinical treatment of solid tumors has been less spectacular than anticipated, whereas efforts in basic and preclinical cancer research made some rather remarkable strides during the last two decades. The major challenge that now faces research investigators in cancer imrnuno-Key words: cancer immunotherapy therapy is to determine the functional characteristics of potentially new molecules, important for cancer immunotherapy in both structural and functional terms, to attempt a correlation of their structure with function and to develop, at the basic and preclinical levels, approaches suitable for potential therapy regimens that can be transferred to the clinic for further development.
๐ SIMILAR VOLUMES
## Abstract This review addresses peptide regions of human tumor liberated protein (TLP) complexes with antigenic activity. The review also deals with antibodies reacting with such proteins, to be used for diagnostic and clinical purposes. We identified peptide sequences of the TLP 100โkDa protein.
Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (i.e., Ta, Tl, and carcinoma in situ) with specific objectives which include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression,
122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 ุ 10 6 LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy
## Abstract No Abtract